New vaccine aims to shield transplant patients from deadly virus
NCT ID NCT02506933
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, training the immune system to fight off CMV. About 100 participants who have had a stem cell transplant will receive either the vaccine or a placebo, and researchers will monitor for CMV infections and other complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMV-MVA Triplex Vaccine
- What this could lead to
- If it works, this vaccine could help prevent dangerous CMV infections in stem cell transplant patients, reducing the need for antiviral drugs and improving recovery.
- What could go wrong
- This is a phase II trial with only 102 participants, so results may not apply to everyone. The vaccine may not provide enough protection, and there is a risk of side effects like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?